Article History
Received: 25 July 2023
Accepted: 2 April 2024
First Online: 19 April 2024
Declarations
:
: This analysis was performed under an approved research protocol by the National Jewish Health central Institutional Review Board (HS# 3034). All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects enrolled in the trial.
: Not applicable.
: JJS is the developer of L-PF-44, L-PF-35 and other questionnaires designed to assess outcomes in patients with various forms of interstitial lung disease. KA and ERFP report no conflict related to this study.